



Certificate of Analysis

www.tocris.com

Product Name: CCS 1477 Catalog No.: 8892 Batch No.: 1

CAS Number: 2222941-37-7

IUPAC Name: (6S)-1-(3,4-Difluorophenyl)-6-[5-(3,5-dimethyl-4-isoxazolyl)-1-(trans-4-methoxycyclohexyl)-1H-benzimidazol-2-yl]-2-

piperidinone

1. PHYSICAL AND CHEMICAL PROPERTIES

Batch Molecular Formula: $C_{30}H_{32}F_2N_4O_3$

Batch Molecular Weight: 534.61 **Physical Appearance:** White solid

DMSO to 100 mM Solubility:

ethanol to 100 mM

Store at -20°C Storage:

Batch Molecular Structure:

2. ANALYTICAL DATA

HPLC: Shows 99.6% purity

¹H NMR: Consistent with structure Mass Spectrum: Consistent with structure

Microanalysis: Carbon Hydrogen Nitrogen

> Theoretical 67.4 6.03 10.48 Found 67.35 10.35 5.96

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use



Product Information

Print Date: Aug 1st 2025

www.tocris.com

Product Name: CCS 1477 Catalog No.: 8892 Batch No.: 1

CAS Number: 2222941-37-7

IUPAC Name: (6S)-1-(3,4-Difluorophenyl)-6-[5-(3,5-dimethyl-4-isoxazolyl)-1-(trans-4-methoxycyclohexyl)-1H-benzimidazol-2-yl]-2-

piperidinone

Description:

CCS 1477 is a selective p300/CBP bromodomain inhibitor. CCS 1477 binds with high affinity to p300 and CBP (K_d values are 1.3 and 1.7 nM, respectively), and with 170/130-fold selectivity compared with BRD4 (K_d = 222 nM). In vitro, CCS 1477 inhibits the proliferation of OPM-2 multiple myeloma cells (Gl_{50} = 5 nM). Also, CCS 1477 inhibits cell proliferation in prostate cancer cell lines and decreases AR- and C-MYC-regulated gene expression. In vivo, CCS 1477 significantly improves survival and reduces tumor size in MOLM16 AML and OPM2 myeloma tumors in subcutaneous xenograft models. CCS 1477 is orally bioavailable. Please see product specific page on www.tocris.com for full description.

Physical and Chemical Properties:

Batch Molecular Formula: $C_{30}H_{32}F_2N_4O_3$

Batch Molecular Weight: 534.61 Physical Appearance: White solid

Minimum Purity: ≥98%

Batch Molecular Structure:

Storage: Store at -20°C

Solubility & Usage Info:

DMSO to 100 mM ethanol to 100 mM

Stability and Solubility Advice:

Some solutions can be difficult to obtain and can be encouraged by rapid stirring, sonication or gentle warming (in a 45-60°C water bath).

Information concerning product stability, particularly in solution, has rarely been reported and in most cases we can only offer a general guide. *Unless contradicted by product-specific protocols or instructions, our standard recommendations apply:

SOLIDS: Provided storage is as stated on the product label and the vial is kept tightly sealed, the product can be stored for up to 6 months from date of receipt.

SOLUTIONS: We recommend that stock solutions, once prepared, are stored aliquoted in tightly sealed vials at -20°C or below and used within 1 month. Wherever possible solutions should be made up and used on the same day.

Licensing Information:

Sold under license from Cell Centric Ltd

References:

Nicosia et al (2023) Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies. Cancer Cell **41** 2136. PMID: 37995682.

Welti et al (2021) Targeting the p300/CBP axis in lethal prostate cancer. Cancer Discov. 11 1118. PMID: 33431496.

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use